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Interleukin (IL)-18 has been described to play a role in several inﬂammatory skin diseases such as eczema and
psoriasis. In this study, we aimed to elucidate keratinocytes as potential targets for IL-18 effects. In human primary
keratinocytes expression of IL-18Ra as well as responses to IL-18 were determined. In keratinocytes freshly isolated
from skin biopsies of lesional atopic dermatitis or psoriasis, we observed a significantly higher expression of the IL-
18Ra as compared with keratinocytes from normal donors. A marked upregulation was induced in vitro upon stim-
ulation with interferon (IFN)cþ tumor necrosis factor (TNF)a or poly I:C. IL-4 led to downregulation of IL-18Ra. IL-18-
induced CXCL10/IP-10 production in freshly isolated keratinocytes from lesional psoriasis as well as in cultured
normal keratinocytes. Furthermore, IL-18 upregulated major histocompatibility complex (MHC) class II expression on
IFNc-stimulated keratinocytes. This was of functional significance as veriﬁed in coculture experiments with CD4þ T
cells in the presence of superantigen. T cells produced significant amounts of IFNc after coculture with IL-18-induced
MHC class II expressing keratinocytes. In conclusion, we have shown that keratinocytes functionally respond to IL-18
with upregulation of MHC II and production of the chemokine CXCL10/IP-10. These ﬁndings further support an
important role of IL-18 in inﬂammatory skin diseases in the epidermal compartment.
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With this study, we aimed to better understand the role of
the pro-inflammatory cytokine interleukin (IL)-18 in the de-
velopment of chronic inflammatory skin diseases such as
atopic dermatitis (AD) and psoriasis.
Keratinocytes are the outermost component of the skin,
and they can be activated by diverse factors to produce a
broad range of pro- and anti-inflammatory mediators. IL-18
has been described to be produced by keratinocytes (Naik
et al, 1999; Companjen et al, 2000; Ohta et al, 2001; Lebre
et al, 2003); however, some debate still exists under which
conditions bioactive IL-18 (as opposed to pro-IL-18) is re-
leased by epidermal cells. In the epidermal compartment, in
addition to keratinocytes, Langerhans cells (LC) also pro-
duce IL-18 (Matsui et al, 1997; Novak et al, 2004), which in
turn contributes to the regulation of LC/dendritic cells (DC)
migration (Cumberbatch et al, 2001; Gutzmer et al, 2003). In
a number of inflammatory skin diseases—such as psoriasis
and AD—IL-18 overexpression in the skin has been dem-
onstrated.
IL-18 activities depend to a large extent on the sur-
rounding micromilieu—resulting in sometimes apparently
oppositional effects. Together with IL-12, IL-18 induces in-
terferon (IFN)g production and IL-12Rb2 expression on T
cells (Xu et al, 1998; Yoshimoto et al, 1998; Chang et al,
2000; Nakahira et al, 2002). Together with IL-2, however, IL-
18 coinduces IL-13 in murine T and NK cells (Hoshino et al,
1999, 2000). When cultured alone or in combination with IL-
4, IL-18 is known to induce murine T cell T-helper type 2
(Th2) differentiation (Yoshimoto et al, 2000). Thus, IL-18 can
promote Th1 or Th2 lineage maturation dependent on the
ambient cytokine milieu and underlying genetic influences
(Nakanishi et al, 2001). On non-T cell populations, IL-18, in
conjunction with IL-3, induces IL-4 and IL-13 production
and histamine release by basophils (Yoshimoto et al, 1999).
Direct effects on macrophages and DC have also been ob-
served, which also includes the recently described chemo-
attraction of human DC by IL-18 and induction of
costimulatory molecules (Gutzmer et al, 2003). So, IL-18 is
an important regulator of both innate and acquired immunity
(Akira, 2000; McInnes et al, 2000). IL-18 expression and
effector function has been described in inflammatory dis-
eases across a broad range of tissues (reviewed in Gracie
et al, 2003).
The receptor of IL-18 is composed of an a-chain (IL-
18Ra) and a b-chain (IL-18Rb or AcPL) (Torigoe et al, 1997;
Born et al, 1998; Dinarello, 1999). Although IL-18Ra repre-
sents the ligand-binding chain, IL-18Rb appears to assist in
the formation of a high-affinity complex and mediates in-
tracellular signals. IL-18R is expressed on a variety of cells
including macrophages, neutrophils, NK cells, endothelial,
and smooth muscle cells (Gerdes et al, 2002). Expression of
IL-18Ra and IL-18Rb on human keratinocytes has been
shown on the mRNA level (Mee et al, 2000) and by
immunohistochemistry with a polyclonal antibody (Koizumi
Abbreviations: AD, atopic dermatitis; DC, dendritic cells; IFN, in-
terferon; IL, interleukin; MAPK, mitogen-activated protein kinase;
MHC, major histocompatibility complex; NF-kB, nuclear factor kB;
SEB, staphylococcal enterotoxin B; SEM, standard error of the
mean; Th2, T-helper type 2; TNF, tumor necrosis factor
Copyright r 2005 by The Society for Investigative Dermatology, Inc.
1225
et al, 2001), but upregulation by any stimulus has not been
described so far. Similar to IL-1, IL-18 signals through the
IL-1R-associated kinase (IRAK) and activates nuclear factor
kB (NF-kB) (Adachi et al, 1998; Kojima et al, 1999).
There are a number of studies pointing to a role of IL-18
for the development of AD. A large body of these data,
however, are obtained in the mouse model (Konishi et al,
2002; Yagi et al, 2002) and cannot be transferred one to one
to the human system. Furthermore, it is important to clearly
differentiate between data obtained from the skin as op-
posed to data obtained from the blood compartment. For
the blood compartment, most studies found elevated IL-18
levels in AD patients, which, in some studies showed a
tendency to correlate with clinical severity scores (El Me-
zzein et al, 2001; Tanaka et al, 2001). Data for the human
skin compartment are lacking. A role of IL-18 in the patho-
genesis of atopy has also been strengthened by the pres-
ence of eight common single-nucleotide polymorphisms in
the promoter regions of IL-18 (Kruse et al, 2003) related to
the atopic phenotype.
Psoriasis is a common cutaneous disorder characterized
by abnormal epidermal proliferation and inflammation char-
acterized by a more Th1-like cytokine pattern. Increased
serum levels as well as increased expression of IL-18 protein
in suprabasal keratinocytes have been described in human
psoriasis (Naik et al, 1999; Gangemi et al, 2003; Pietrzak
et al, 2003). Ohta et al (2001) could demonstrate that IL-18
mRNA is overexpressed in psoriatic lesional skin and that IL-
18 protein is actively synthesized in psoriatic epidermis.
In this study, we have demonstrated that the IL-18Ra is
upregulated on keratinocytes in inflammatory skin diseases.
Furthermore, we have shown that keratinocytes functionally
respond to IL-18 with upregulation of major histocompat-
ibility complex (MHC) class I and II and production of the
chemokine CXCL10. These findings point to the fact that IL-
18 may contribute to chronification of inflammatory skin
diseases also by direct effects on human keratinocytes.
Results
Expression of IL-18Ra, IL-12Rb1, and IL-12Rb2 on hu-
man primary keratinocytes IL-18Ra was found to be ex-
pressed on human primary keratinocytes. In all experi-
ments, there was a low basal expression of IL-18Ra on
keratinocytes. IL-18Ra was moderately upregulated by IFNg
(5–10 ng per mL) alone (Fig 1). When receptor expression of
Figure 1
Expression of interleukin (IL)-18Ra on human primary keratinocytes. IL-18Ra expression was determined on normal human primary kera-
tinocytes by flow cytometry 24 h after stimulation. A histogram of one representative experiment is shown in (A). (B) Receptor expression determined
in individual experiments was normalized to the corresponding medium value to allow summary of different experiments. Original (unprocessed)
geometric mean data were submitted to the t test and compared with the expression level of non-stimulated (ns) cells. For all stimulation shown, at
least six independent experiments were performed. Interferon (IFN)g (10 ng per mL), IL-18 (50 ng per mL), IL-12 (50 ng per mL), tumor necrosis factor
(TNF)a (200 U per mL), poly I:C (200 ng per mL). (C, D) (n¼3), the effect of IL-4 on IL-18R expression is shown. Keratinocytes were incubated with IL-
4 (50 ng per mL in C) 16 h before addition of IFNgþ second signal. MFI, mean fluorescense intensity; pI:C, poly I:C.
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IFNg-stimulated keratinocytes was compared with expres-
sion of matched unstimulated cells, upregulation of IL-18R
was significant as determined by a paired the t test (p¼
0.03). Expression was increased more than 3-fold by IFNg in
combination with tumor necrosis factor (TNF)a and more
than 2-fold by IFNg in combination with poly I:C (Fig 1). In
contrast to the results described for cells of the lymphocyte
lineage, we could not find any effect of IL-12 or IL-23 (in a
dose range from 1 to 50 ng per mL) on the expression of IL-
18Ra (not shown). This may reflect different responsiveness
and signalling toward IL-12 in keratinocytes as compared
with T cells or NK cell. IL-1b or GM-CSF also did not show
significant effects on the expression level of IL-18Ra.
IL-12Rb1 was found to be expressed on keratinocytes
and slightly but reproducibly upregulated by IFNg (mean
6.9, standard error of the mean (SEM) 1.36; non-stimulated:
mean 5.3, SEM 0.839; p¼ 0.03 as determined by the paired
t test; n¼ 10), IFNa (200 U per mL; mean 11.7, SEM 1.5;
non-stimulated: mean 9.5, SEM 2.0; p¼0.035 as deter-
mined by a paired the t test; n¼ 7) or IFNgþTNFa (mean
6.4, SEM 1.4, non-stimulated: mean 5.6, SEM 1.17; p¼0.02
as determined by a paired the t test; n¼ 9), but not by IL-18,
IL-12, TNFa, or poly I:C (data not shown). Upregulation of
IL-12Rb1 by these stimuli was much lower (i.e. less than
2-fold) than upregulation of IL-18Ra. In a total of ten
independent experiments, IL-12Rb2 was not detectable on
keratinocytes with or without addition of stimuli (IL-1b,
IL-18, IL-12, TNFa, IFNg, poly I:C, IFNa, IFNb, combination
of IFN with cytokines, or addition of cyclosporin A; van
Rietschoten et al, 2001).
IL-4 downregulates the expression of IL-18Ra on human
keratinocytes Many inflammatory skin diseases are asso-
ciated with a local ‘‘mixed’’ cytokine pattern both of Th2 and
Th1 cytokines. In a subsequent series, we thus tested the
influence of the major ‘‘Th2’’ cytokine IL-4 on IL-18R ex-
pression. Given alone, IL-4 did not exert any significant ef-
fect on receptor expression. But IL-4 given prior (16 h) to
incubation with the pairs of cytokine that had the strongest
effects on IL-18R expression on keratinocytes led to a re-
ceptor downregulation (Fig 1C). The effect was concentra-
tion dependent, with 50–100 ng per mL of IL-4 having the
most pronounced effects (Fig 1D). When IL-4 was given
simultaneously with the stimulation, downregulation of the
receptor was not evident.
IL-18Ra expression is upregulated in skin lesions of
psoriasis and AD All surface markers used in the study
were verified to stain for trypsin-insensitive epitopes (as
assessed for the trypsin concentration and incubation pe-
riod used). We isolated keratinocytes from skin biopsies
taken from lesional psoriasis—which is now considered to
be ‘‘Th1’’ associated—and spontaneous lesions of AD—
which is both Th2 and Th1 associated or from normal skin.
Upon isolation, keratinocytes were analyzed within 2 h for
expression of IL-18Ra. The same instrument settings were
used for each experiment. A more than 5-fold higher ex-
pression of the receptor could be observed on keratin-
ocytes from lesional psoriasis and a 2-fold higher
expression was observed on keratinocytes from AD skin
as compared with normal skin (Fig 2).
IL-18 signals via NF-jB in human keratinocytes Keratin-
ocytes showed activation of the NF-kB-signalling pathway
upon IL-18 stimulation as detected by nuclear translocation.
This was demonstrated by using a FACS analysis method
as described before (Foulds, 1997). IL-18 alone was able to
induce nuclear translocation. The IL-18 effect was blocked
by the presence of neutralizing anti-IL-18 antibody during
the stimulation procedure (Fig 3).
IL-18 induces CXCL10 production, but not IL-6, IL-8
production, or expression of costimulatory or adhesion
molecules in human primary keratinocytes Keratin-
ocytes are potent producers of the chemokine CXCL10
that attracts CXCR3-expressing Th1 cells (Bonecchi et al,
1998; Boorsma et al, 1998). IFNg is a known strong inducer
of CXCL10 production by keratinocytes, which was con-
firmed in this study. As shown here, IL-18-induced CXCL10
Figure2
Expression of interleukin (IL)-18R in chronic inflammatory skin
diseases. IL-18Ra expression was determined on freshly isolated
keratinocytes derived from lesional atopic dermatitis (AD) (n¼3) or
psoriasis skin (n¼5) or from normal skin (n¼ 4). Geometric mean of
matched isotype was subtracted from geometric mean obtained with
the specific IL-18Ra antibody in each experiment. Exemplary histo-
grams of IL-18Ra expression on ex vivo keratinocytes from a healthy
individual and from lesional AD and psoriasis are depicted.
Figure3
Interleukin (IL)-18 signals via nuclear factor jB (NF-jB) in human
primary keratinocytes. NF-kBp65 was stained in intact nuclei isolated
from normal human keratinocytes. Cells were stimulated with IL-18 (50
ng per mL) for 30 min. Where indicated, stimulation was performed in
the presence of blocking antibody (10 mg per mL). The left histogram
depicts one representative experiment performed with a blocking anti-
IL-18R antibody. ns, non-stimulated.
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about 3-fold in the picogram per milliliter range after over-
night incubation. Moreover, IL-18 could further increase
CXCL10 production by more than 50% in IFNg-treated ker-
atinocytes (Fig 4A). CXCL10 induction was also observable in
freshly isolated keratinocytes from lesional psoriasis skin in-
cubated overnight with IL-18. The induction level of unstim-
ulated to stimulated keratinocytes was significantly higher in
psoriasis as compared with normal keratinocytes (Fig 4B).
In contrast to data found for human DC (Gutzmer et al,
2003) and human fibroblast/endothelial cells (Morel et al,
2001), we could not find an increased CD54 expression in-
duced by IL-18 on human primary keratinocytes. Cost-
imulatory molecules were not affected either (CD40, CD80,
CD86). Negative results were also obtained for CD44 and
TLR2 (data not shown). Using the cytometric bead array
(CBA), we could not observe consistently increased IL-8, IL-
6, IL-10, IL-12p40, or IL-1b in the supernatant of human
primary keratinocytes stimulated with IL-18. FasL expres-
sion or apoptosis induction—as described for other cell
types such as NK cells—were not observed in human pri-
mary keratinocytes under the influence of IL-18.
IL-18 induces MHC class I and II expression on human
keratinocytes IL-18-induced MHC class I and II expres-
sion on human keratinocytes, known as non-professional
antigen-presenting cells. Overnight incubation of keratin-
ocytes with 5 ng per mL IL-18 resulted in upregulation of cell
surface expression of MHC class I (Fig 5). In contrast, IL-18
did not consistently induce an upregulation of MHC I in
human blood monocytes in six different healthy donors
tested (data not shown). Higher concentration of IL-18 failed
to further increase MHC I expression on keratinocytes.
IL-18 alone had no marked effect on MHC class II. In the
presence of low doses of IFNg (5–10 ng per mL), however,
IL-18 was able to increase cell surface expression of MHC
class II by more than 50% on human keratinocytes (Fig 6A
and B).
IL-18-induced MHC class II expression in human kera-
tinocytes was of functional significance in a coculture
system with CD4þ T cells The IL-18-induced MHC II ex-
pression was of functional significance as indirectly deter-
mined by stimulation of purified CD4þ T cells (10
independent experiments were performed; in six experi-
ments, autologous CD4þ T cells were used and in four
experiments heterologous highly purified CD4þ T cells) in
the presence of the staphylococcal enterotoxin B (SEB),
which functions as a superantigen: T cells were stimulated
with SEB in the presence of cultured keratinocytes that had
been pretreated with IFNg alone or with IFNgþ IL-18 (stimuli
were carefully washed out before start of the coculture).
Figure 4
Interleukin (IL)-18 induction of CXCL10 production in human ker-
atinocytes. CXCL10 production of cultured normal keratinocytes in
passage one to four cultured in 24-well plates in 500 mL of culture
medium were left unstimulated (ns), stimulated with IL-18 (50 ng per
mL) alone, or in combination with interferon (IFN)g (10 ng per mL) (A;
n¼14 (left), n¼ 11 (right)). Supernatants were harvested after 24 h and
analyzed by ELISA. Freshly isolated keratinocytes from lesional pso-
riasis skin or healthy skin were stimulated overnight with IL-18 (B). The
fold induction of CXCL10 secretion in IL-18-stimulated compared with
non-stimulated keratinocytes is given (n¼7 in each group).
Figure5
Interleukin (IL)-18 induces major histocompatibility complex (MHC)
class I upregulation in human keratinocytes. Human keratinocytes
were stimulated with IL-18 (5 ng per mL) for 24 h. MHC I expression
was determined by flow cytometry. The histogram depicts an exem-
plary experiment performed with the blocking IL-18R antibody (10 mg
per mL).
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IFNgþ IL-18 pre-treatment of keratinocytes led to higher
production of IFNg by T cells after coincubation in the pres-
ence of SEB (Fig 6C). In addition, T cells produced signif-
icantly higher amounts of IFNg when cell-to-cell contacts to
keratinocytes were allowed compared with T cells that were
separated from keratinocytes in a transwell system (Fig 6C).
IL-12 does not act synergistically with IL-18 on human
keratinocytes We carefully tested for synergistic effects of
IL-12 or IL-23 and IL-18. For the parameters examined
(CXCL10 production, MHC class I and II expression), IL-12
did not act in synergy with IL-18 on human keratinocytes.
For none of the IL-18 effects found we could observe a
cooperation of the two cytokines as it has been described
for numerous other effects. This may be because of differ-
ent IL-12-signalling pathways in keratinocytes as compared
with blood-derived cells.
Discussion
Keratinocytes represent the major constituent of the skin
and participate actively in the skin immune system by pro-
ducing various soluble mediators. Keratinocyte-derived
chemokines are important for the recruitment and activa-
tion of immune cells, and the formation of the T cell-rich
infiltrate that characterizes chronic inflammatory skin dis-
eases such as allergic contact dermatitis, psoriasis, or AD.
In these skin diseases, T cells actually invade the epidermal
compartment, thus allowing T cell keratinocyte interaction.
Keratinocytes are viewed as non-professional, tolerizing
APC in normal skin. Activated keratinocytes, however, pro-
duce inflammatory cytokines and express MHC class II
molecules and CD54. They also express costimulatory mol-
ecules such as CD80 (only upon stimulation) and CD40.
Thus, there is increasing evidence that keratinocytes di-
rectly participate in cutaneous immunologic diseases (Fan
et al, 2003).
IL-18 has been shown to have a broad range of effector
functions beyond lymphocyte activation that implicate IL-18
as an important regulator of both innate and acquired im-
munity (Akira, 2000; McInnes et al, 2000). IL-18-mediated
processes have been implicated in a number of chronic in-
flammatory disorders. Our study further highlights the role
that IL-18 may play in chronic inflammatory skin diseases
by its capacity to activate keratinocytes.
Figure 6
Interleukin (IL)-18 induces functionally active major histocompatibility complex (MHC) class II expression in human keratinocytes. Ker-
atinocytes were incubated overnight with interferon (IFN)g (5 ng per mL) and IL-18 (50 ng per mL). MHC class II was upregulated by IL-18 as
determined by flow cytometry (A, B). (B) Eleven independent experiments are summarized. MHC II was significantly upregulated by IFNg and
IFNgþ IL-18 as determined by the t test. The difference between IFNg- and IFNgþ IL-18-stimulated keratinocytes in MHC II expression was
significant as determined by paired the t test (p¼0.03). (C) Purified CD4þ T cells from healthy donors were incubated with cultured keratinocytes
from healthy individuals that had been exposed to IFNg or IFNgþ IL-18. These stimuli were carefully washed out before start of the coculture.
Coculture was performed in the presence of the superantigen staphylococcal enterotoxin B (SEB) (100 pg per mL) for 2 h in keratinocyte growth
medium. CD4þ T cells (in six experiments autologous, and in four heterologous highly purified CD4þ T cells were used) were then transferred to
IAB medium and cultured for another 40 h. Supernatants were harvested and IFNg was determined by ELISA. Values found for CD4þ T cells
cultured with IFNg pre-treated keratinocytes in the presence of SEB were set to 100%. Difference in IFNg of CD4þ T cells cocultured with IFNg-
treated as compared with IFNgþ IL-18-treated keratinocytes was significant as determined by a paired the t test with the raw data (p¼0.02). Where
indicated, cell-to-cell contact was averted using a 0.2 mm transwell.
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Expression of IL-18Ra and IL-18Rb on human keratin-
ocytes has been shown on the mRNA level (Mee et al,
2000), but upregulation by any stimulus has not been in-
vestigated so far. In this work, we show in support of the
mRNA data constitutive expression of IL-18Ra at the pro-
tein level, which can be markedly upregulated by IFNg in
combination with either TNFa or double-stranded RNA (poly
I:C).
The IL-18R complex can be upregulated on naı¨ve T cells,
Th1, NK cells, and B cells by IL-12 (Yoshimoto et al, 1998;
Sareneva et al, 2000). By contrast, IL-12 did not upregulate
the expression of IL-18Ra on keratinocytes on the protein
level as shown in our study, nor on the mRNA level (Mee
et al, 2000). Although a response of keratinocytes toward IL-
12 has been described (Schwarz et al, 2002), it has not been
shown so far that they express the IL-12 receptor. Here, we
could show that human keratinocytes express the IL-
12Rb1, but not the high-affinity receptor IL-12Rb2. Differ-
ent receptor expression and signalling toward IL-12 in
keratinocytes as compared with lymphocytes could be
responsible for the lack to interfere with the ‘‘IL-18 system’’.
On the other hand, IL-4 was effective in downregulating
the receptor as it has been described for lymphocytes (Sa-
reneva et al, 2000; Smeltz et al, 2001, 2002). It is known that
keratinocytes are good responders to IL-4, whereas the
spectrum of the biological effects of this cytokine to kera-
tinocytes is quite broad (Albanesi et al, 2000) and includes
pro-inflammatory as well as anti-inflammatory effects.
The IL-18R complex-induced-signalling pathways are
shared with other IL-1R family members. These involve
MyD88, IRAK, TRAF6, and NF-kB nuclear translocation
(Adachi et al, 1998; Kojima et al, 1999). Dominant-negative
transfectants of IkBa have been shown to inhibit IL-18-de-
pendent IkBa degradation and NF-kB activation in KG-1
cells (Kojima et al, 1999). In addition to IRAK/TRAF6 sig-
nalling, evidence suggests a role for mitogen-activated pro-
tein kinase (MAPK) in IL-18 signalling. Thus, activation of the
MAPK p38 and ERK by IL-18 was detected in a human NK
cell line (Kalina et al, 2000). IL-18 signalling via NF-kB, but
not MAPK, has been shown for human monocytes (Dai et al,
2004); activation of both NF-kB and MAPK pathways has
been shown in synovial fibroblasts (Morel et al, 2002). Our
data extend the notion that IL-18 signals via NF-kB pathway
also in human keratinocytes. In the study by Lee et al (2004),
human epithelial cells (A549) were stably transfected with
the IL-18Rb chain and responded to IL-18 with increased
production of IL-1, IL-6, and IL-8. Signalling via the MAPK
p38 but not NF-kB pathway was observed in the study.
Differences from our observations might be explained by
different culture systems. We used human primary keratin-
ocytes and have not been working with cell lines. Further-
more, our cells were not transfected and were cultured in
serum-free medium.
Keratinocytes seem to have a unique IL-18R regulation
and response pattern toward IL-18 compared with other cell
types. Here we report on secretion of CXCL10 upon IL-18
stimulation by human keratinocytes, which has not been
described before. As mentioned above, clear differences
exist in receptor regulation compared with cells of the
lymphocyte lineage/NK cells. Also, the effects described
here are not all comparable with those found for IL-18 in
non-lymphocytic cells. In contrast to data found on human
DC (Gutzmer et al, 2003) and human fibroblast/endothelial
cells (Morel et al, 2001), we could not find an increased
CD54 expression induced by IL-18 on human primary ker-
atinocytes. Costimulatory molecules were not affected ei-
ther (CD40, CD80, CD86). IL-18 induces IL-6, IL-8, CD54,
and matrix metalloproteinase expression in vascular
smooth muscle cells, endothelial cells, and macrophages
(Gerdes et al, 2002). Using the CBA, we could not observe a
consistent IL-18-induced production of IL-8, TNFa, IL-1b,
IL-10, IL-12p40, or IL-6 in human primary keratinocytes.
Furthermore, we could not detect increased apoptosis in
our cultured keratinocytes stimulated with IL-18, nor could
we detect induction of FasL by IL-18 as it has been de-
scribed for NK cells. Yamanaka et al (2000) have shown
in skin-specific IL-1 converting enzyme-transgenic mice,
which constitutively secrete mature IL-18, spontaneous de-
velopment of skin ulcers with massive keratinocyte apop-
tosis. According to our data, IL-18 does not seem to play a
direct role in skin apoptosis in the human system.
Our data support the notion that IL-18 is involved in the
pathogenesis of local Th1 responses in chronic inflamma-
tory skin diseases such as psoriasis and AD (Ohta et al,
2001; Novak et al, 2004). Here we show that IL-18Ra is
upregulated in both diseases and that keratinocytes from
lesional psoriasis are more responsive to IL-18 than cells
from normal skin. In eczematous skin diseases, the devel-
opment of skin lesions from acute to chronic is accompa-
nied by a switch from a more Th2 cytokine pattern to a Th1-
like cytokine pattern expressed in the cutaneous lesions
(Leung and Bieber, 2003). The process of the shift from Th2
(Wittmann et al, 2004) to Th1 dominance in the lesions is
largely unknown but it is speculated that IL-12 (from FceRI-
activated inflammatory dendritic epidermal cells; Novak
et al, 2004, skin invading cells such as macrophages or
eosinophils) together with IL-18 leads to the activation of
Th1 cells in this process. IL-18 (together with IL-12) may not
only act directly on infiltrating T cells to produce IFNg, but
keratinocytes may be directly involved in perpetuating a
Th1-like reaction pattern. At sites of acute inflammation, the
IL-18R is upregulated on keratinocytes, rendering them
highly responsive toward IL-18. By production of CXCL10,
CXCR3 expressing IFNg-producing T cells are attracted to
the site of inflammation. Here they encounter MHC class II
expressing keratinocytes, which in combination with super-
antigens—which have been shown to be present in AD ep-
idermis and psoriasis (Leung et al, 1995)—induce an T cell
stimulation resulting in high IFNg production.
As acute flareup lesions of AD have been investigated in
this study, the presence of the Th2 cytokines IL-4/IL-13
might be responsible for the lower expression level of IL-
18R on AD keratinocytes as compared with keratinocytes
freshly isolated from psoriasis lesions. Presumably, a higher
expression level might be found in the more Th1-like chronic
phase of the disease.
The data presented here also support an involvement of
epithelial cells themselves in the protective effect of IL-18 in
the situation of epidermal viral infection by upregulation of
MHC class I. It is known that IL-18 plays a part in the
clearance of viruses. IL-18 is protective in a murine model of
Herpes simplex virus (HSV) infection (Fujioka et al, 1999;
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Harandi et al, 2001; Malmgaard and Paludan, 2003). Down-
modulation of IL-18-induced immune responses by human
papilloma virus (HPV) oncoproteins may contribute to viral
pathogenesis or carcinogenesis. This may arise via HPV
binding to the IL-18R, thus preventing IL-18 induction of
IFNg (Cho et al, 2001). So, in epidermal viral infections such
as HSV, HPV, and varicella-zoster virus, in addition to in-
ducing IFNg, and activating CD8þ T cells, IL-18 produced
by keratinocytes may act in an autocrine fashion.
But important questions remain. To completely under-
stand the ‘‘IL-18’’ system in the skin and the outcome of
IL-18 ‘‘activity’’ on the skin immune response, it is neces-
sary to further investigate the complex interaction of the
players in this system: caspases 1 and 3 (Akita et al, 1997)
activity, proteinase 3 activity, IL-18R binding IL-1H (Pan
et al, 2001), and secretion of IL-18 BP (Muhl et al, 2000).
Finally, the position of IL-18 in the functional hierarchy of
pro-inflammatory cytokines in chronic inflammation is not
fully resolved.
Materials and Methods
Cytokines and reagents All cytokines were used as purified re-
combinant human preparations. Human recombinant IL-13 (50 ng
per mL), TNFa (200 U per mL), and CXCL10 (10 or 100 ng per mL)
were purchased from Tebu/Peprotech (Frankfurt a. M., Germany);
IFNg (5–10 ng per mL), IFNb1a (300 U per mL), and IL-1b (200 U per
mL) from ImmunoTools (Friesoythe, Germany); IL-4 (20–50 ng per
mL), IL-12 (1 or 10 ng per mL), IL-23 (10–50 ng per mL), IL-18 (5 or
50 ng per mL), and mouse anti-human IL-18Rb mAb (clone 132,016
for neutralizing of IL-18 effects: 10 mg per mL) from R&D Systems
(Wiesbaden, Germany); and GM-CSF (500 U per mL, Essex Pharma,
Munich, Germany), poly I:C (200 ng per mL, Sigma-Aldrich, De-
isenhofen, Germany), IFNa2a (200 U per mL, Roche Applied Sci-
ence, Mannheim, Germany), and SEB (100 pg per mL) were
purchased from Toxin Technologies/Alexis (Gruenberg, Germany).
Cell isolation and culture Peripheral blood mononuclear cells
were separated by Ficoll–Hypaque density gradient centrifugation.
CD4þ T cells were isolated using a negative selection kit (Miltenyi
Biotech, Bergisch Gladbach, Germany). Purity of the resulting
CD4þ T cells wasX95% as verified by flow cytometry analysis of
CD4þ T cells (mouse anti-human CD4 monoclonal antibody;
Beckman-Coulter, Krefeld, Germany). After separation, cells were
resuspended in Iscove medium (Biochrom, Berlin, Germany) sup-
plemented with 4% human AB serum.
Primary cultures of normal human keratinocytes were prepared
from foreskin of children undergoing surgery. Skin specimens were
cut into small pieces and incubated overnight in dispase II (2.4 U
per mL, Roche Applied Science) at 41C. Epidermis was detached
from the dermis with fine forceps and incubated in Hank’s solution
with 0.25% trypsin (Sigma-Aldrich) for 20 min at 371C. Trypsin ac-
tivity was stopped by addition of FCS (Life Technolologies,
Karlsruhe, Germany). The cell suspension was passed through a
40 mm sterile gauze. The obtained keratinocytes were washed
twice and single-cell suspension of keratinocytes was cultured in
serum-free keratinocytes growth medium (Keratinocyte Growth
Medium 2 Kit; PromoCell GmbH, Heidelberg, Germany). All cell
cultures were incubated in a humidified atmosphere containing 5%
CO2 at 371C and were used at the passage two to five. Hydro-
cortisone-free medium was used for all experiments. The purity of
keratinocytes was verified by the expression of the epithelial mark-
er cytokeratin (mouse anti-human cytokeratin antibody, clone:
MNF-116, DakoCytomation, Hamburg, Germany) and the fibro-
blast-specific marker ASO2 (CD90, Dianova GmbH, Hamburg,
Germany). All cells (more than 95%) were found to be uniformly
positive for cytokeratin but not for CD90.
Assessment of IL-18Ra in fresh human skin biopsies Punch
skin biopsies of 4 mm were obtained from patients with active
psoriasis, AD, and healthy individuals after informed written con-
sent. All psoriasis patients (type II psoriasis) suffered from plaque
psoriasis (no psoriasis arthritis); AD patients were affected by the
extrinsic form and presented with acute flareup lesions. None of
the patients received any systemic immunosuppression or anti-
histamine treatment. The study was approved by the Ethics com-
mittee of the Hannover Medical School, Hannover and was
conducted according to the Declaration of Helsinki Principles. For
obtaining fresh keratinocytes, skin biopsies were immediately cut
into small pieces and incubated in 0.25% trypsin (Sigma-Aldrich)
for 20 min at 371C. The digestion was stopped by addition of FCS
(Life Technologies). The single-cell suspension was prepared after
passing the cells through a 40 mm sterile gauze. Assessment of IL-
18Ra on keratinocytes was performed by flow cytometry. Keratin-
ocytes were identified by cytokeratin-positive staining. More than
85% of the cells were positive for cytokeratin. Eight to 15% CD3þ
cells could be detected, but no CD1aþ cells.
Flow cytometric analysis of intracellular and membrane mol-
ecules Expression of surface antigens was assessed as de-
scribed previously (Wittmann et al, 2002). The following PE- or
FITC-labelled monoclonal anti-human antibodies were used: IL-
18Ra (clone 70,625 R&D Systems), IL-12Rb1 (clone 2.4E6), IL-
12Rb2 (clone 2B6/12b2), and MHC class II (clone G46-6 (L243), BD
Biosciences, Heidelburg, Germany), MHC class I (clone W6/32,
Biosource, Solingen, Germany), CD54 (clone 84H10), and CD40
(clone MAB89, Beckman-Coulter). All surface markers used in the
study were verified to stain for trypsin-insensitive epitopes (as as-
sessed for the trypsin concentration and incubation period used).
Some keratinocyte cultures did not respond to IFNg (less than 1.5-
fold increase of MHC I or II expression as determined by shift in
geometric mean); these experiments were excluded from analysis.
Cytokeratin (DakoCytomation) was detected by intracellular staining
using the Cytofix/Cytoperm kit (BD Biosciences). Stained cells were
measured by flow cytometry (FACSCalibur) and analyzed using
CELLQuestPro software (BD Biosciences). Geometric mean values
were analyzed to determine differences in receptor expression.
NF-jB staining We have used a flow cytometric technique to
study translocation of NF-kB from the cytoplasm to the nuclei of
the cell as published previously (Foulds, 1997). In brief, after stim-
ulation of the cells (as indicated), intact nuclei were isolated using
the CycleTest PLUS DNA Reagent Kit (BD Biosciences) according
to the manufacturer’s instruction. 2.5 mg per mL of mouse mono-
clonal anti-human NF-kB (p65) antibody (clone 112A1021, Im-
genex, San Diego, California) or isotype-matched controls were
then added for 20 min at room temperature followed by further
20 min incubation with 1 ml goat anti-mouse FITC antibody (Beckman-
Coulter). Two hundred microliters of cold propidium iodide (PI) so-
lution was added to the nuclei and the preparation was incubated
for further 10 min. Acquisition of stained nuclei was carried out on a
FACS Calibur (BD Biosciences) equipped with an electronic dou-
blet discrimination module. The singlet population was analyzed
for FITC staining.
Quantiﬁcation of cytokines and chemokines IFNg in the cell-
free supernatants of cultured human CD4þ T cells was measured
after 48 h. IFNg was detected by ELISA (Ready-Set-Go human
IFNg ELISA, Biocarta, Hamburg, Germany). The concentration of
human CXCL10 was determined in supernatants of human kera-
tinocytes according to the manufacturer’s instruction (IP-10, Opt-
EIA, BD Biosciences). For analysis of CXCL10 production by IL-18
alone, experiments with a very high spontaneous CXCL10 pro-
duction (4150 pg per mL CXCL10 production by non-stimulated
cultured keratinocytes) were excluded. The CBA human inflam-
mation kit allowing simultaneous detection of IL-12p40, IL-1b, IL-6,
IL-8, and TNFa, and IL-10 assay was performed according to the
manufacturer&aposs instruction (BD Biosciences).
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Statistical analysis Comparative data were analyzed using the t
test (data are depicted in columns) or paired t test (paired data are
depicted). The software used to perform the statistical analysis
was SigmaStat for Windows version 2.03. Mean values  SEM
are depicted. In the figures, p-valueo0.05, po0.02, and
po0.01.
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